Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 8Genitourinary 2Breast 2

Conditions

Breast Neoplasms 7Neoplasm Metastasis 2Humoral Hypercalcemia Of Malignancy 2Pain 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Ibandronic Acid × Breast × Clear all
NCT00301886 2013-11-13

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

SWOG Cancer Research Network

Phase 3 Withdrawn
Breast

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

NCT00326820 2013-03-13

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Wales Cancer Trials Unit

Phase 3 Unknown
1,404 enrolled
Breast

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡